Mucoadhesive Poloxamer-Based Hydrogels for the Release of HP-β-CD-Complexed Dexamethasone in the Treatment of Buccal Diseases

Oral lichen planus (OLP) is an ongoing and chronic inflammatory disease affecting the mucous membrane of the oral cavity. Currently, the treatment of choice consists in the direct application into the buccal cavity of semisolid formulations containing a corticosteroid molecule to decrease inflammato...

Full description

Bibliographic Details
Main Authors: Raul Diaz-Salmeron, Balthazar Toussaint, Nicolas Huang, Etienne Bourgeois Ducournau, Gabriel Alviset, Sophie Goulay Dufaÿ, Hervé Hillaireau, Amélie Dufaÿ Wojcicki, Vincent Boudy
Format: Article
Language:English
Published: MDPI AG 2021-01-01
Series:Pharmaceutics
Subjects:
Online Access:https://www.mdpi.com/1999-4923/13/1/117
id doaj-5d18e66bb55243d88476c09800aa7984
record_format Article
spelling doaj-5d18e66bb55243d88476c09800aa79842021-01-19T00:04:29ZengMDPI AGPharmaceutics1999-49232021-01-011311711710.3390/pharmaceutics13010117Mucoadhesive Poloxamer-Based Hydrogels for the Release of HP-β-CD-Complexed Dexamethasone in the Treatment of Buccal DiseasesRaul Diaz-Salmeron0Balthazar Toussaint1Nicolas Huang2Etienne Bourgeois Ducournau3Gabriel Alviset4Sophie Goulay Dufaÿ5Hervé Hillaireau6Amélie Dufaÿ Wojcicki7Vincent Boudy8Département de Recherche et Développement Pharmaceutique, Agence Générale des Equipements et Produits de Santé (AGEPS), 75005 Paris, FranceDépartement de Recherche et Développement Pharmaceutique, Agence Générale des Equipements et Produits de Santé (AGEPS), 75005 Paris, FranceInstitut Galien Paris Saclay, Université Paris-Saclay, CNRS, 92296 Châtenay-Malabry, FranceDépartement de Recherche et Développement Pharmaceutique, Agence Générale des Equipements et Produits de Santé (AGEPS), 75005 Paris, FranceDépartement de Recherche et Développement Pharmaceutique, Agence Générale des Equipements et Produits de Santé (AGEPS), 75005 Paris, FranceDépartement de Recherche et Développement Pharmaceutique, Agence Générale des Equipements et Produits de Santé (AGEPS), 75005 Paris, FranceInstitut Galien Paris Saclay, Université Paris-Saclay, CNRS, 92296 Châtenay-Malabry, FranceDépartement de Recherche et Développement Pharmaceutique, Agence Générale des Equipements et Produits de Santé (AGEPS), 75005 Paris, FranceDépartement de Recherche et Développement Pharmaceutique, Agence Générale des Equipements et Produits de Santé (AGEPS), 75005 Paris, FranceOral lichen planus (OLP) is an ongoing and chronic inflammatory disease affecting the mucous membrane of the oral cavity. Currently, the treatment of choice consists in the direct application into the buccal cavity of semisolid formulations containing a corticosteroid molecule to decrease inflammatory signs and symptoms. However, this administration route has shown various disadvantages limiting its clinical use and efficacy. Indeed, the frequency of application and the incorrect use of the preparation may lead to a poor efficacy and limit the treatment compliance. Furthermore, the saliva clearance and the mechanical stress present in the buccal cavity also involve a decrease in the mucosal exposure to the drug. In this context, the design of a new pharmaceutical formulation, containing a steroidal anti-inflammatory, mucoadhesive, sprayable and exhibiting a sustained and controlled release seems to be suitable to overcome the main limitations of the existing pharmaceutical dosage forms. The present work reports the formulation, optimization and evaluation of the mucoadhesive and release properties of a poloxamer 407 thermosensitive hydrogel containing a poorly water-soluble corticosteroid, dexamethasone acetate (DMA), threaded into hydroxypropyl-beta-cyclodextrin (HP-β-CD) molecules. Firstly, physicochemical properties were assessed to ensure suitable complexation of DMA into HP-β-CD cavities. Then, rheological properties, in the presence and absence of various mucoadhesive agents, were determined and optimized. The hydration ratio (0.218–0.191), the poloxamer 407 (15–17 wt%) percentage and liquid-cyclodextrin state were optimized as a function of the gelation transition temperature, viscoelastic behavior and dynamic flow viscosity. Deformation and resistance properties were evaluated in the presence of various mucoadhesive compounds, being the sodium alginate and xanthan gum the most suitable to improve adhesion and mucoadhesion properties. Xanthan gum was shown as the best agent prolonging the hydrogel retention time up to 45 min. Furthermore, xanthan gum has been found as a relevant polymer matrix controlling drug release by diffusion and swelling processes in order to achieve therapeutic concentration for prolonged periods of time.https://www.mdpi.com/1999-4923/13/1/117mucoadhesioncontrolled-drug releasepolysaccharidespoloxamerscyclodextrins
collection DOAJ
language English
format Article
sources DOAJ
author Raul Diaz-Salmeron
Balthazar Toussaint
Nicolas Huang
Etienne Bourgeois Ducournau
Gabriel Alviset
Sophie Goulay Dufaÿ
Hervé Hillaireau
Amélie Dufaÿ Wojcicki
Vincent Boudy
spellingShingle Raul Diaz-Salmeron
Balthazar Toussaint
Nicolas Huang
Etienne Bourgeois Ducournau
Gabriel Alviset
Sophie Goulay Dufaÿ
Hervé Hillaireau
Amélie Dufaÿ Wojcicki
Vincent Boudy
Mucoadhesive Poloxamer-Based Hydrogels for the Release of HP-β-CD-Complexed Dexamethasone in the Treatment of Buccal Diseases
Pharmaceutics
mucoadhesion
controlled-drug release
polysaccharides
poloxamers
cyclodextrins
author_facet Raul Diaz-Salmeron
Balthazar Toussaint
Nicolas Huang
Etienne Bourgeois Ducournau
Gabriel Alviset
Sophie Goulay Dufaÿ
Hervé Hillaireau
Amélie Dufaÿ Wojcicki
Vincent Boudy
author_sort Raul Diaz-Salmeron
title Mucoadhesive Poloxamer-Based Hydrogels for the Release of HP-β-CD-Complexed Dexamethasone in the Treatment of Buccal Diseases
title_short Mucoadhesive Poloxamer-Based Hydrogels for the Release of HP-β-CD-Complexed Dexamethasone in the Treatment of Buccal Diseases
title_full Mucoadhesive Poloxamer-Based Hydrogels for the Release of HP-β-CD-Complexed Dexamethasone in the Treatment of Buccal Diseases
title_fullStr Mucoadhesive Poloxamer-Based Hydrogels for the Release of HP-β-CD-Complexed Dexamethasone in the Treatment of Buccal Diseases
title_full_unstemmed Mucoadhesive Poloxamer-Based Hydrogels for the Release of HP-β-CD-Complexed Dexamethasone in the Treatment of Buccal Diseases
title_sort mucoadhesive poloxamer-based hydrogels for the release of hp-β-cd-complexed dexamethasone in the treatment of buccal diseases
publisher MDPI AG
series Pharmaceutics
issn 1999-4923
publishDate 2021-01-01
description Oral lichen planus (OLP) is an ongoing and chronic inflammatory disease affecting the mucous membrane of the oral cavity. Currently, the treatment of choice consists in the direct application into the buccal cavity of semisolid formulations containing a corticosteroid molecule to decrease inflammatory signs and symptoms. However, this administration route has shown various disadvantages limiting its clinical use and efficacy. Indeed, the frequency of application and the incorrect use of the preparation may lead to a poor efficacy and limit the treatment compliance. Furthermore, the saliva clearance and the mechanical stress present in the buccal cavity also involve a decrease in the mucosal exposure to the drug. In this context, the design of a new pharmaceutical formulation, containing a steroidal anti-inflammatory, mucoadhesive, sprayable and exhibiting a sustained and controlled release seems to be suitable to overcome the main limitations of the existing pharmaceutical dosage forms. The present work reports the formulation, optimization and evaluation of the mucoadhesive and release properties of a poloxamer 407 thermosensitive hydrogel containing a poorly water-soluble corticosteroid, dexamethasone acetate (DMA), threaded into hydroxypropyl-beta-cyclodextrin (HP-β-CD) molecules. Firstly, physicochemical properties were assessed to ensure suitable complexation of DMA into HP-β-CD cavities. Then, rheological properties, in the presence and absence of various mucoadhesive agents, were determined and optimized. The hydration ratio (0.218–0.191), the poloxamer 407 (15–17 wt%) percentage and liquid-cyclodextrin state were optimized as a function of the gelation transition temperature, viscoelastic behavior and dynamic flow viscosity. Deformation and resistance properties were evaluated in the presence of various mucoadhesive compounds, being the sodium alginate and xanthan gum the most suitable to improve adhesion and mucoadhesion properties. Xanthan gum was shown as the best agent prolonging the hydrogel retention time up to 45 min. Furthermore, xanthan gum has been found as a relevant polymer matrix controlling drug release by diffusion and swelling processes in order to achieve therapeutic concentration for prolonged periods of time.
topic mucoadhesion
controlled-drug release
polysaccharides
poloxamers
cyclodextrins
url https://www.mdpi.com/1999-4923/13/1/117
work_keys_str_mv AT rauldiazsalmeron mucoadhesivepoloxamerbasedhydrogelsforthereleaseofhpbcdcomplexeddexamethasoneinthetreatmentofbuccaldiseases
AT balthazartoussaint mucoadhesivepoloxamerbasedhydrogelsforthereleaseofhpbcdcomplexeddexamethasoneinthetreatmentofbuccaldiseases
AT nicolashuang mucoadhesivepoloxamerbasedhydrogelsforthereleaseofhpbcdcomplexeddexamethasoneinthetreatmentofbuccaldiseases
AT etiennebourgeoisducournau mucoadhesivepoloxamerbasedhydrogelsforthereleaseofhpbcdcomplexeddexamethasoneinthetreatmentofbuccaldiseases
AT gabrielalviset mucoadhesivepoloxamerbasedhydrogelsforthereleaseofhpbcdcomplexeddexamethasoneinthetreatmentofbuccaldiseases
AT sophiegoulaydufay mucoadhesivepoloxamerbasedhydrogelsforthereleaseofhpbcdcomplexeddexamethasoneinthetreatmentofbuccaldiseases
AT hervehillaireau mucoadhesivepoloxamerbasedhydrogelsforthereleaseofhpbcdcomplexeddexamethasoneinthetreatmentofbuccaldiseases
AT ameliedufaywojcicki mucoadhesivepoloxamerbasedhydrogelsforthereleaseofhpbcdcomplexeddexamethasoneinthetreatmentofbuccaldiseases
AT vincentboudy mucoadhesivepoloxamerbasedhydrogelsforthereleaseofhpbcdcomplexeddexamethasoneinthetreatmentofbuccaldiseases
_version_ 1724332604757377024